



## Monkeypox Vaccine Development and Vaccination Strategies

Guest Editors:

**Dr. Natalie Prow**

Hull York Medical School,  
University of York, York, UK

**Dr. Preethi Eldi**

Experimental Therapeutics  
Laboratory, Clinical and Health  
Science Unit, University of South  
Australia, Adelaide, SA, Australia

Deadline for manuscript  
submissions:

**31 May 2025**

### Message from the Guest Editors

Monkeypox is a zoonotic disease that was once endemic in west and central Africa, caused by the orthopoxvirus, monkeypox virus. However, recent cases have been confirmed in many nonendemic countries outside of Africa. The WHO declared the ongoing monkeypox outbreak to be a public health emergency of international concern on 23 July 2022. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets and via fomites such as towels and bedding. Strategies for prevention, such as the smallpox vaccine has been recommended in high-risk persons. Two vaccines are currently available, JYNNEOSTM (live, replication-incompetent vaccinia virus) and ACAM2000® (live, replication-competent vaccinia virus). The development of vaccines against the monkeypox virus and different vaccination strategies are urgently needed. In this context, this Special Issue invites you to submit your research related to scientific advances in the field of monkeypox vaccine development and vaccination strategies.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)